Literature DB >> 9515890

Community-acquired pneumonia guidelines--an international comparison: a view from Europe.

M Woodhead1.   

Abstract

Following an outline that details the pathogens causing community-acquired pneumonia (CAP) identified in studies from Europe, this article reviews the guidelines for the management of CAP in four European countries--France, Italy, Spain, and the United Kingdom. The method behind the development of each document is described, followed by a comparison of the scope of each document. All four documents provide guidelines for the management of two groups of patients--the severely ill and the nonseverely ill patient. A penicillin or macrolide feature for the nonseverely ill and the combination of a third-generation cephalosporin plus a macrolide for the severely ill patient are described in all four guidelines. Despite their different origins and methods, these four guidelines have more similarities than differences--the latter serving to emphasize some of the areas that require further research in this important condition. An important area for research is the impact that these guidelines have on practice and especially on clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9515890     DOI: 10.1378/chest.113.3_supplement.183s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Pneumococcal Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

2.  Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy.

Authors:  A. Saito; Fumio Miki; Kotaro Oizumi; Naoto Rikitomi; Akira Watanabe; Hironobu Koga; Yoshito Niki; Nobuchika Kusano
Journal:  J Infect Chemother       Date:  1999-06       Impact factor: 2.211

3.  Community acquired pneumonia in elderly people. Addition of erythromycin is not currently justified.

Authors:  M Woodhead
Journal:  BMJ       Date:  1998-11-28

4.  Mycoplasma pneumoniae respiratory tract infections among Greek children.

Authors:  M Almasri; E Diza; A Papa; M Eboriadou; E Souliou
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

Review 5.  New developments in antibacterial choice for lower respiratory tract infections in elderly patients.

Authors:  Anna Maria Ferrara; Anna Maria Fietta
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Respiratory syncytial virus infection in hospitalized children older than 2 years with community-acquired pneumonia.

Authors:  M Almasri; A Papa; E Souliou; K Haidopoulou; M Eboriadou
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

7.  Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.

Authors:  Julio A Ramirez; Angel C Cooper; Timothy Wiemken; David Gardiner; Timothy Babinchak
Journal:  BMC Infect Dis       Date:  2012-07-19       Impact factor: 3.090

Review 8.  Pathogenesis and Treatment of Neurologic Diseases Associated With Mycoplasma pneumoniae Infection.

Authors:  Renato D'Alonzo; Elisabetta Mencaroni; Lorenza Di Genova; Daniela Laino; Nicola Principi; Susanna Esposito
Journal:  Front Microbiol       Date:  2018-11-20       Impact factor: 5.640

Review 9.  [Definition of low respiratory tract infections].

Authors:  B Housset
Journal:  Med Mal Infect       Date:  2006-07-11       Impact factor: 2.152

10.  Choosing New Therapies for Gonorrhoea: We Need to Consider the Impact on the Pan-Neisseria Genome. A Viewpoint.

Authors:  Chris Kenyon; Jolein Laumen; Sheeba Manoharan-Basil
Journal:  Antibiotics (Basel)       Date:  2021-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.